RU2000124535A - INTRODUCED BY THE ORAL WAY OF THE GALENOV FORM WITH FAST DELIVERY AND WITH A PROLONGED DIVISION, INCLUDING THE AMPLIFIED ABSORPTION AGENT, AND THE APPLICATION OF THIS STRENGTHENING ABSORPTION AGENT. - Google Patents
INTRODUCED BY THE ORAL WAY OF THE GALENOV FORM WITH FAST DELIVERY AND WITH A PROLONGED DIVISION, INCLUDING THE AMPLIFIED ABSORPTION AGENT, AND THE APPLICATION OF THIS STRENGTHENING ABSORPTION AGENT.Info
- Publication number
- RU2000124535A RU2000124535A RU2000124535/14A RU2000124535A RU2000124535A RU 2000124535 A RU2000124535 A RU 2000124535A RU 2000124535/14 A RU2000124535/14 A RU 2000124535/14A RU 2000124535 A RU2000124535 A RU 2000124535A RU 2000124535 A RU2000124535 A RU 2000124535A
- Authority
- RU
- Russia
- Prior art keywords
- active substance
- form according
- galenova
- ionizable
- group
- Prior art date
Links
- 238000010521 absorption reaction Methods 0.000 title claims 13
- 230000002035 prolonged Effects 0.000 title 1
- 238000005728 strengthening Methods 0.000 title 1
- 239000000126 substance Substances 0.000 claims 22
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 230000002708 enhancing Effects 0.000 claims 9
- 235000014113 dietary fatty acids Nutrition 0.000 claims 7
- 239000000194 fatty acid Substances 0.000 claims 7
- -1 lipid compounds Chemical class 0.000 claims 7
- 150000004665 fatty acids Chemical class 0.000 claims 6
- 150000001768 cations Chemical class 0.000 claims 5
- 125000005456 glyceride group Chemical group 0.000 claims 5
- 239000003623 enhancer Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 4
- BVDRUCCQKHGCRX-UHFFFAOYSA-N 2,3-dihydroxypropyl formate Polymers OCC(O)COC=O BVDRUCCQKHGCRX-UHFFFAOYSA-N 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 3
- 229920005862 polyol Polymers 0.000 claims 3
- 150000003077 polyols Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims 2
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims 2
- GQZXNSPRSGFJLY-UHFFFAOYSA-N Hypophosphorous acid Chemical compound OP=O GQZXNSPRSGFJLY-UHFFFAOYSA-N 0.000 claims 2
- 239000006096 absorbing agent Substances 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 2
- 125000005418 aryl aryl group Chemical group 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 150000002170 ethers Chemical class 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 claims 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 229960001157 Acamprosate calcium Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N Captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 230000036698 Distribution coefficient Effects 0.000 claims 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N Glyceryl behenate Chemical class CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 Metformin Drugs 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 229940068965 Polysorbates Drugs 0.000 claims 1
- BUVGWDNTAWHSKI-UHFFFAOYSA-L acamprosate calcium Chemical compound [Ca+2].CC(=O)NCCCS([O-])(=O)=O.CC(=O)NCCCS([O-])(=O)=O BUVGWDNTAWHSKI-UHFFFAOYSA-L 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 239000003613 bile acid Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N diguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 150000002191 fatty alcohols Chemical class 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 229920000151 polyglycol Polymers 0.000 claims 1
- 239000010695 polyglycol Substances 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229910052712 strontium Inorganic materials 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000005550 wet granulation Methods 0.000 claims 1
- 238000009736 wetting Methods 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Claims (1)
в которой Х выбирают из:
R означает С1-С7алкильный радикал;
R1, R2, R3 выбирают из группы, включающей атом водорода и С1-С7 алкильный радикал;
А означает группу формулы:
где v и w равны 0, 1, 2,
или означает группу формулы
где R5, R6 независимо друг от друга выбирают из группы, включающей атом водорода, С1-С7алкильный радикал, арильный радикал, имеющий от 6 до 14 атомов углерода, и гетероарильный радикал, выбранный из ряда, включающего фурил, тиенил и тиазолил, причем арильные и гетероарильные радикалы могут нести 1-3 заместителя, выбранных из ряда, включающего С1-С7алкильную группу, галоген или трифторметильную группу, и t равно 1-3,
R4 выбирают из группы, включающей атом водорода, C1-С7алкильный радикал, радикал CF3, арильный радикал, имеющий от 6 до 14 атомов углерода и гетероарильный радикал, выбранный из ряда, включающего фурил, тиенил и тиазолил, причем арильные и гетероарильные радикалы могут нести 1-3 заместителя, выбранных из ряда, включающего C1-С7алкильную группу, галоген или трифторметильную группу,
М означает одновалентный металл (Na, К, Li) или двухвалентный металл (Са, Mg, Sr, Zn),
m равно 1 или 2,
р равно 1-2 и
q равно 1-2,
причем значения р и q выбирают таким образом, чтобы обеспечить электрическую нейтральность соли.8. Galenova form according to any one of paragraphs. 1-3, characterized in that the active substance is a compound of the formula
in which X is chosen from:
R means a C 1 -C 7 alkyl radical;
R 1 , R 2 , R 3 are selected from the group consisting of a hydrogen atom and a C 1 -C 7 alkyl radical;
And means a group of the formula:
where v and w are 0, 1, 2,
or means a group of the formula
where R 5 , R 6 are independently selected from the group consisting of a hydrogen atom, a C 1 -C 7 alkyl radical, an aryl radical having from 6 to 14 carbon atoms, and a heteroaryl radical selected from the series including furyl, thienyl, and thiazolyl, the aryl and heteroaryl radicals may have 1-3 substituents selected from the series comprising a C 1 -C 7 alkyl group, a halogen or trifluoromethyl group, and t is 1-3,
R 4 is selected from the group consisting of a hydrogen atom, a C 1 -C 7 alkyl radical, a CF 3 radical, an aryl radical having from 6 to 14 carbon atoms and a heteroaryl radical selected from the series including furyl, thienyl and thiazolyl, and aryl and heteroaryl radicals may have 1-3 substituents selected from the group consisting of a C 1 -C 7 alkyl group, a halogen or trifluoromethyl group,
M means a monovalent metal (Na, K, Li) or a bivalent metal (Ca, Mg, Sr, Zn),
m is 1 or 2,
p is 1-2 and
q is 1-2,
moreover, the values of p and q are chosen in such a way as to ensure electrical neutrality of the salt.
10. Галенова форма по п. 8, отличающаяся тем, что действующее вещество имеет формулу (I), в которой
11. Галенова форма по п. 8, отличающаяся тем, что действующее вещество, которое является гидрофильным или ионизируемым в физиологических средах, представляет собой акампросат кальция.9. The galenic form according to claim. 8, characterized in that the active substance has the formula (I), in which
10. Galenova form according to claim 8, characterized in that the active substance has the formula (I), in which
11. The galenic form according to claim. 8, characterized in that the active substance, which is hydrophilic or ionizable in physiological media, is acamprosate calcium.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR98/02143 | 1998-02-23 | ||
FR9802143A FR2775188B1 (en) | 1998-02-23 | 1998-02-23 | IMMEDIATE RELEASE ORAL EXTENDED RELEASE GALENIC FORM COMPRISING AN ABSORPTION PROMOTING AGENT AND USE OF THE ABSORPTION PROMOTING AGENT |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000124535A true RU2000124535A (en) | 2002-08-20 |
RU2228201C2 RU2228201C2 (en) | 2004-05-10 |
Family
ID=9523244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000124535/15A RU2228201C2 (en) | 1998-02-23 | 1999-02-16 | Oral galenics with rapid release and sustained-release comprising absorption-enhancing agent and application of this absorption-enhancing agent |
Country Status (28)
Country | Link |
---|---|
US (2) | US6426087B1 (en) |
EP (2) | EP1410791B1 (en) |
JP (1) | JP4828020B2 (en) |
KR (1) | KR100587181B1 (en) |
CN (1) | CN1182837C (en) |
AP (1) | AP2000001943A0 (en) |
AR (2) | AR018109A1 (en) |
AT (2) | ATE408399T1 (en) |
AU (1) | AU750785B2 (en) |
BR (1) | BR9908121A (en) |
CA (1) | CA2321267C (en) |
CZ (1) | CZ299366B6 (en) |
DE (2) | DE69917750T2 (en) |
DK (2) | DK1410791T3 (en) |
ES (2) | ES2222695T3 (en) |
FR (1) | FR2775188B1 (en) |
HK (1) | HK1035142A1 (en) |
HU (1) | HU226732B1 (en) |
ID (1) | ID26022A (en) |
NO (1) | NO20004190L (en) |
OA (1) | OA11454A (en) |
PL (2) | PL201851B1 (en) |
PT (2) | PT1056445E (en) |
RU (1) | RU2228201C2 (en) |
SI (2) | SI1056445T1 (en) |
SK (2) | SK285188B6 (en) |
WO (1) | WO1999042086A1 (en) |
ZA (1) | ZA991408B (en) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9925127D0 (en) | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
FR2805462B1 (en) * | 2000-02-24 | 2003-08-15 | Therabel Res | NEW ORAL GALENIC FORM WITH EXTENDED RELEASE OF MOLSIDOMINE |
DE10026699A1 (en) | 2000-05-30 | 2001-12-06 | Basf Ag | Formulation based on heparin, glycosaminoglycan or heparinoid and use of the formulation and the formulation base |
US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
SE0200475D0 (en) * | 2002-02-15 | 2002-02-15 | Ltp Lipid Technologies Provide | Oral pharmaceutical preparation |
US7667053B2 (en) | 2002-04-12 | 2010-02-23 | Merck & Co., Inc. | Bicyclic amides |
US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
FR2845289B1 (en) * | 2002-10-04 | 2004-12-03 | Ethypharm Sa | SPHEROIDS, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS. |
WO2004032860A2 (en) | 2002-10-07 | 2004-04-22 | Chiron Corporation | Hiv vaccine formulations |
US20040151769A1 (en) * | 2002-12-31 | 2004-08-05 | Boehringer Ingelheim International Gmbh | Film coated tablet containing an extract of red vine leaves |
ITRM20030074A1 (en) * | 2003-02-21 | 2004-08-22 | Pharmacia Italia Spa | SEMI-SOLID FORMULATIONS WITH IMMEDIATE RELEASE AGREEMENTS |
US20040241252A1 (en) * | 2003-05-29 | 2004-12-02 | Abney Christopher Charles | Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same |
WO2005060942A1 (en) * | 2003-12-19 | 2005-07-07 | Aurobindo Pharma Ltd | Extended release pharmaceutical composition of metformin |
US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
WO2005102342A1 (en) * | 2004-04-22 | 2005-11-03 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders ii |
US20080181946A1 (en) * | 2004-05-14 | 2008-07-31 | Braj Bhushan Lohray | Controlled Release Delivery System For Metformin |
PT1765292T (en) | 2004-06-12 | 2017-12-29 | Collegium Pharmaceutical Inc | Abuse-deterrent drug formulations |
US20060024370A1 (en) * | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
EP1789048A1 (en) * | 2004-09-03 | 2007-05-30 | Boehringer Ingelheim International GmbH | Method for the treatment of attention deficit hyperactivity disorder |
MX2007003813A (en) * | 2004-10-01 | 2007-04-24 | Firmenich & Cie | Perfuming or flavouring microcapsules comprising an explosion suppressant. |
CA2599937A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
CA2599721A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
PE20061245A1 (en) * | 2005-03-30 | 2007-01-06 | Generex Pharm Inc | COMPOSITIONS FOR ORAL TRANSMUCOUS TRANSMISSION OF METFORMIN |
JP2008540356A (en) * | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Drug abuse treatment methods |
EP1888071A1 (en) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Method for the treatment of drug-induced sexual dysfunction |
EP1888070A1 (en) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Method for the treatment of sexual dysfunctions due to medical conditions |
EP1896021B1 (en) * | 2005-06-21 | 2009-04-15 | Merck Patent GmbH | Solid pharmaceutical preparation containing (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chroman |
EP1745788A1 (en) * | 2005-07-22 | 2007-01-24 | KTB Tumorforschungsgesellschaft mbH | Acyglycerophospholipids for treating cancer and cachexia |
JP2009503020A (en) | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Use of flibanserin in the treatment of obesity |
US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
WO2007048803A1 (en) * | 2005-10-29 | 2007-05-03 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
WO2007106957A1 (en) * | 2006-03-21 | 2007-09-27 | Laboratoires Smb S.A. | Multiple units controlled-release floating dosage forms |
JP2009536176A (en) * | 2006-05-09 | 2009-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Use of flibanserin for the treatment of postmenopausal sexual desire disorders |
ES2336719T3 (en) | 2006-06-30 | 2010-04-15 | Boehringer Ingelheim International Gmbh | FLIBANSERINE FOR THE TREATMENT OF URINARY INCONTINENCE AND RELATED DISEASES. |
EP2043648A1 (en) * | 2006-07-14 | 2009-04-08 | Boehringer Ingelheim International GmbH | Use of flibanserin for the treatment of sexual disorders in females |
WO2008019996A2 (en) * | 2006-08-14 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
CL2007002214A1 (en) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP |
WO2008022932A2 (en) * | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
US20080081142A1 (en) * | 2006-10-03 | 2008-04-03 | Zeik Douglas B | Articles and methods for applying color on surfaces |
EP1952803A1 (en) * | 2007-01-23 | 2008-08-06 | KTB-Tumorforschungs GmbH | Solid pharmaceutical dosage form containing hydrogenated phospholipids |
EP2217564A1 (en) * | 2007-09-07 | 2010-08-18 | XenoPort, Inc. | Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
WO2009033079A1 (en) * | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
PE20091188A1 (en) | 2007-09-12 | 2009-08-31 | Boehringer Ingelheim Int | COMPOUND 1- [2- (4- (3-TRIFLUOROMETIL-PHENYL) PIPERAZIN-1-IL) ETHYL] -2,3-DIHYDRO-1H-BENZIMIDAZOL-2-ONA (FLIBANSERIN), ITS ADDITION SALTS AND PHARMACEUTICAL COMPOSITIONS THAT THEY CONTAIN |
EP2042165A1 (en) * | 2007-09-28 | 2009-04-01 | Swiss Caps Rechte und Lizenzen AG | Hot-melt filled soft capsules |
US20090099253A1 (en) * | 2007-10-15 | 2009-04-16 | Xenoport, Inc. | Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use |
CA2638240C (en) * | 2008-08-29 | 2010-02-02 | Alexander Macgregor | Method of treating dysglycemia and glucose excursions |
AU2009319183B2 (en) | 2008-11-27 | 2014-06-05 | B.R.A.I.N. Biotechnology Research And Information Network Ag | Hydrophobins as surface active proteins as excipients in solid pharmaceutical formulations |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
WO2011074961A1 (en) | 2009-12-18 | 2011-06-23 | Frieslandcampina Nederland Holding B.V. | Co-processed tablet excipient composition its preparation and use |
JP5546900B2 (en) * | 2010-02-25 | 2014-07-09 | ライオン株式会社 | Panaxatriol stabilizing composition |
MX346203B (en) | 2010-09-28 | 2017-03-09 | Depomed Inc | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract. |
US20130143867A1 (en) * | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
KR102055859B1 (en) * | 2011-12-02 | 2019-12-13 | 싱크로뉴런 인코포레이티드 | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US20150246060A1 (en) | 2013-03-15 | 2015-09-03 | Iceutica Inc. | Abiraterone Acetate Formulation and Methods of Use |
JP2016514707A (en) * | 2013-03-15 | 2016-05-23 | アイシューティカ インク.Iceutica Inc. | Abiraterone acetate preparation |
EP3003297A4 (en) | 2013-06-05 | 2017-04-19 | Synchroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US20150157646A1 (en) | 2013-09-27 | 2015-06-11 | Iceutica Inc. | Abiraterone Steroid Formulation |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
US12042566B2 (en) | 2017-05-17 | 2024-07-23 | Confluence Pharmaceuticals, Llc | Formulations of homotaurines and salts thereof |
WO2023025672A1 (en) | 2021-08-25 | 2023-03-02 | Basf Se | Direct tableting auxiliary composition |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI63335B (en) * | 1979-02-02 | 1983-02-28 | Orion Yhtymae Oy | FARING REFERENCE FOR A TABLETTER WITH A LIGHT LIGHT OF AN EFFECTIVE |
FR2457281A1 (en) * | 1979-05-23 | 1980-12-19 | Meram Lab | NOVEL 3-AMINOPROPANESULFONIC ACID DERIVATIVES WITH ENHANCED MEMBRANE ACTIVITY |
GB8524421D0 (en) * | 1985-10-03 | 1985-11-06 | Boots Co Plc | Therapeutic agents |
JPS62265226A (en) * | 1986-05-12 | 1987-11-18 | Fujisawa Pharmaceut Co Ltd | Pharmaceutical for oral administration |
US5190748A (en) * | 1988-11-22 | 1993-03-02 | Hoffmann-La Roche Inc. | Absorption enhancement of antibiotics |
ZA898331B (en) * | 1988-11-22 | 1990-07-25 | Hoffmann La Roche | Pharmaceutical compositions |
US5139786A (en) * | 1989-07-07 | 1992-08-18 | Ciba-Geigy Corporation | Topical formulations |
JPH03275633A (en) * | 1990-03-23 | 1991-12-06 | Teikoku Seiyaku Co Ltd | Absorbefacient for physiologically active polypeptide |
US5138786A (en) | 1991-07-17 | 1992-08-18 | Fischer Michael G | Insta-guard firearm protection |
IT1255895B (en) * | 1992-10-20 | 1995-11-17 | Laura Chiodini | PHARMACEUTICAL COMPOSITIONS CONTAINING A CALCITONIN |
DE4432757A1 (en) * | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmaceutical preparation containing metformin and process for its preparation |
US5858398A (en) * | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
-
1998
- 1998-02-23 FR FR9802143A patent/FR2775188B1/en not_active Expired - Fee Related
-
1999
- 1999-02-16 PL PL377398A patent/PL201851B1/en unknown
- 1999-02-16 DE DE69917750T patent/DE69917750T2/en not_active Expired - Lifetime
- 1999-02-16 EP EP04001294A patent/EP1410791B1/en not_active Expired - Lifetime
- 1999-02-16 AU AU31408/99A patent/AU750785B2/en not_active Ceased
- 1999-02-16 HU HU0100970A patent/HU226732B1/en not_active IP Right Cessation
- 1999-02-16 SI SI9930637T patent/SI1056445T1/en unknown
- 1999-02-16 PT PT99913165T patent/PT1056445E/en unknown
- 1999-02-16 CN CNB998032182A patent/CN1182837C/en not_active Expired - Fee Related
- 1999-02-16 RU RU2000124535/15A patent/RU2228201C2/en not_active IP Right Cessation
- 1999-02-16 DK DK04001294T patent/DK1410791T3/en active
- 1999-02-16 DK DK99913165T patent/DK1056445T3/en active
- 1999-02-16 AP APAP/P/2000/001943A patent/AP2000001943A0/en unknown
- 1999-02-16 JP JP2000532103A patent/JP4828020B2/en not_active Expired - Fee Related
- 1999-02-16 PT PT04001294T patent/PT1410791E/en unknown
- 1999-02-16 DE DE69939605T patent/DE69939605D1/en not_active Expired - Lifetime
- 1999-02-16 SK SK1255-2000A patent/SK285188B6/en not_active IP Right Cessation
- 1999-02-16 BR BR9908121-0A patent/BR9908121A/en not_active Application Discontinuation
- 1999-02-16 SK SK5107-2005A patent/SK286248B6/en not_active IP Right Cessation
- 1999-02-16 KR KR1020007009307A patent/KR100587181B1/en not_active IP Right Cessation
- 1999-02-16 ES ES99913165T patent/ES2222695T3/en not_active Expired - Lifetime
- 1999-02-16 US US09/622,663 patent/US6426087B1/en not_active Expired - Lifetime
- 1999-02-16 WO PCT/EP1999/000994 patent/WO1999042086A1/en active IP Right Grant
- 1999-02-16 AT AT04001294T patent/ATE408399T1/en active
- 1999-02-16 CA CA002321267A patent/CA2321267C/en not_active Expired - Fee Related
- 1999-02-16 ID IDW20001870A patent/ID26022A/en unknown
- 1999-02-16 AT AT99913165T patent/ATE268164T1/en active
- 1999-02-16 SI SI9931019T patent/SI1410791T1/en unknown
- 1999-02-16 EP EP99913165A patent/EP1056445B1/en not_active Expired - Lifetime
- 1999-02-16 ES ES04001294T patent/ES2314302T3/en not_active Expired - Lifetime
- 1999-02-16 CZ CZ20002940A patent/CZ299366B6/en not_active IP Right Cessation
- 1999-02-16 PL PL342162A patent/PL191415B1/en unknown
- 1999-02-22 ZA ZA9901408A patent/ZA991408B/en unknown
- 1999-02-23 AR ARP990100731A patent/AR018109A1/en active IP Right Grant
-
2000
- 2000-08-22 NO NO20004190A patent/NO20004190L/en not_active Application Discontinuation
- 2000-08-22 OA OA1200000231A patent/OA11454A/en unknown
-
2001
- 2001-08-17 HK HK01105794A patent/HK1035142A1/en not_active IP Right Cessation
-
2002
- 2002-03-19 US US10/100,084 patent/US6514524B1/en not_active Expired - Lifetime
-
2008
- 2008-06-04 AR ARP080102354A patent/AR066843A2/en active IP Right Grant
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2000124535A (en) | INTRODUCED BY THE ORAL WAY OF THE GALENOV FORM WITH FAST DELIVERY AND WITH A PROLONGED DIVISION, INCLUDING THE AMPLIFIED ABSORPTION AGENT, AND THE APPLICATION OF THIS STRENGTHENING ABSORPTION AGENT. | |
RU2228201C2 (en) | Oral galenics with rapid release and sustained-release comprising absorption-enhancing agent and application of this absorption-enhancing agent | |
US6468559B1 (en) | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods | |
WO2005063218A3 (en) | Pharmaceutical formulations of bisphosphonates | |
PL192080B1 (en) | Pharmaceutic composition in the form of self-emulsifiable formulation of lipophilic compounds | |
DE69927963D1 (en) | GELABLE PHARMACEUTICAL COMPOSITIONS | |
JP2011201914A (en) | Clear oil-containing pharmaceutical composition | |
CA1275930C (en) | Therapeutic agents containing 2-(2-fluoro-4-biphenylyl)-propionic acid | |
JPS63174922A (en) | Oral therapy system | |
HRP20010243B1 (en) | Compositions containing diphosphonic acids | |
MXPA01009840A (en) | Novel formulations comprising lipid-regulating agents. | |
RU2002122744A (en) | NEW SELF-EMULSING SYSTEM OF DELIVERY OF MEDICINES | |
JP2002540174A (en) | Novel formulation containing lipid regulator | |
AU2003248969A1 (en) | Pharmaceutical formulation comprising cyclosporin, propylene glycol ester and non-ionic surfactant | |
US5736542A (en) | Pharmaceutical compositions containing a staurosporine | |
US5665384A (en) | Oily capsules of ketoprofen | |
RU2004127237A (en) | SOLID DRUG FORM WITH SLOW / CONTROLLED RELEASE AS A NEW MEDICINAL DELIVERY SYSTEM WITH A REDUCED DOSE RISK OF DOSE | |
HRP20020154B1 (en) | Pharmaceutical compositions for oral and topical administration | |
UA72522C2 (en) | Microgranules insoluble in gastric fluid, method of manufacture and pharmaceutical formulation | |
ES2905251T3 (en) | Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin-based drug | |
EA200700735A1 (en) | CAPSULES LERKANIDIPINA | |
ATE324103T1 (en) | CONTROLLED RELEASE MEDICINAL PREPARATION CONTAINING TRAMADOL HYDROCHLORIDE | |
KR101859200B1 (en) | Pharmaceutical composition of monoacetyldiacylglycerol compound for oral administration and solid pharmaceutical preparation | |
JPH0234325B2 (en) | SHISHUSHITSUKANCHIRYOYOSOSEIBUTSU | |
JPH10330250A (en) | Menatetrenone oily formulation |